Oncology

Where Do Biosimilars Fit in to the Treatment Landscape?

May 29th 2020

Market-Access Considerations for Biosimilars in Oncology

May 29th 2020

Determining Biosimilars' Role in the Formulary

May 29th 2020

Switching to Available Biosimilars in Oncology

May 29th 2020

Biosimilars: Addressing Roadblocks to Market Adoption

May 29th 2020

Are Biosimilar Costs a Factor for Patients?

May 29th 2020

Biosimilars in Oncology: Equivalency and Cost

May 29th 2020

Current State of Biosimilars: Approval, Availability, and Efficacy

May 29th 2020

Biosimilars in Oncology: Addressing Awareness

May 29th 2020

Biosimilar Pegfilgrasim Cuts OCM Expense, ASCO Study Finds

May 29th 2020

By Tony Hagen

A study presented at ASCO20 Virtual demonstrated the power of biosimilar pegfilgrastim to lower costs in the Oncology Care Model (OCM), where pegfilgrastim expense amounts to 5.3% of the total cost of cancer care.